BioCryst Pharmaceuticals Overview

  • Year Founded
  • 1986

Year Founded

  • Status
  • Public

  • Employees
  • 435

Employees

  • Stock Symbol
  • BCRX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $7.22
  • (As of Friday Closing)

BioCryst Pharmaceuticals General Information

Description

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 4505 Emperor Boulevard
  • Suite 200
  • Durham, NC 27703
  • United States
+1 (919)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 4505 Emperor Boulevard
  • Suite 200
  • Durham, NC 27703
  • United States
+1 (919)

BioCryst Pharmaceuticals Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioCryst Pharmaceuticals Stock Performance

As of 20-Nov-2026, BioCryst Pharmaceuticals’s stock price is $7.22. Its current market cap is $1.86B with 257M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$7.22 $7.30 $6.23 - $11.22 $1.86B 257M 4.94M -$1.24

BioCryst Pharmaceuticals Financials Summary

As of 30-Sep-2026, BioCryst Pharmaceuticals has a trailing 12-month revenue of $962M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,568,871 2,076,315 2,036,762 1,674,647
Revenue 961,510 874,837 450,712 331,412
EBITDA (286,962) 336,984 (1,938) (132,112)
Net Income (359,656) 263,861 (88,881) (226,539)
Total Assets 591,070 514,158 490,420 516,960
Total Debt 784,454 438,874 808,742 825,148
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BioCryst Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BioCryst Pharmaceuticals‘s full profile, request access.

Request a free trial

BioCryst Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-m
Pharmaceuticals
Durham, NC
435 As of 2025

Richmond, CA
 

Wilmington, DE
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BioCryst Pharmaceuticals Competitors (47)

One of BioCryst Pharmaceuticals’s 47 competitors is Sangamo Therapeutics, a Formerly VC-backed company based in Richmond, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sangamo Therapeutics Formerly VC-backed Richmond, CA
Incyte Formerly VC-backed Wilmington, DE
Spero Therapeutics Formerly VC-backed Cambridge, MA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 47 competitors. Get the full list »

BioCryst Pharmaceuticals Patents

BioCryst Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026217680-A1 Inhibitors of complement protein c5 Pending 08-Apr-2025
WO-2026174171-A1 Inhibitors of complement protein c5 Pending 14-Feb-2025
WO-2026174196-A1 Tricyclic inhibitors of complement protein c5 Pending 14-Feb-2025
WO-2026170177-A1 Method of prophylaxis to prevent attacks of hereditary angioedema in pediatric patients Pending 10-Feb-2025
WO-2026151989-A1 Use of avoralstat in the treatment of diabetic macular edema and related ocular diseases Pending 12-Jan-2025 A61K31/4418
To view BioCryst Pharmaceuticals’s complete patent history, request access »

BioCryst Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BioCryst Pharmaceuticals Acquisitions (1)

BioCryst Pharmaceuticals’s most recent deal was a Merger/Acquisition with Astria Therapeutics for . The deal was made on 23-Jan-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Astria Therapeutics 23-Jan-2026 Merger/Acquisition Drug Discovery
To view BioCryst Pharmaceuticals’s complete acquisitions history, request access »

BioCryst Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

30.27 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view BioCryst Pharmaceuticals’s complete esg history, request access »

BioCryst Pharmaceuticals FAQs

  • When was BioCryst Pharmaceuticals founded?

    BioCryst Pharmaceuticals was founded in 1986.

  • Where is BioCryst Pharmaceuticals headquartered?

    BioCryst Pharmaceuticals is headquartered in Durham, NC.

  • What is the size of BioCryst Pharmaceuticals?

    BioCryst Pharmaceuticals has 435 total employees.

  • What industry is BioCryst Pharmaceuticals in?

    BioCryst Pharmaceuticals’s primary industry is Pharmaceuticals.

  • Is BioCryst Pharmaceuticals a private or public company?

    BioCryst Pharmaceuticals is a Public company.

  • What is BioCryst Pharmaceuticals’s stock symbol?

    The ticker symbol for BioCryst Pharmaceuticals is BCRX.

  • What is the current stock price of BioCryst Pharmaceuticals?

    As of 20-Nov-2026 the stock price of BioCryst Pharmaceuticals is $7.22.

  • What is the current market cap of BioCryst Pharmaceuticals?

    The current market capitalization of BioCryst Pharmaceuticals is $1.86B.

  • What is BioCryst Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for BioCryst Pharmaceuticals is $962M.

  • Who are BioCryst Pharmaceuticals’s competitors?

    Sangamo Therapeutics, Incyte, Spero Therapeutics, Sorrento Therapeutics, and Gilead are some of the 47 competitors of BioCryst Pharmaceuticals.

  • What is BioCryst Pharmaceuticals’s annual earnings per share (EPS)?

    BioCryst Pharmaceuticals’s EPS for 12 months was -$1.24.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process